INSIGHT-005: A new stratum of the explorative, open-labeled, phase I INSIGHT study to evaluate the feasibility and safety, as well as preliminary efficacy, of subcutaneous injections with IMP321 (eftilagimod alpha) in combination with PD-L1 inhibitor (avelumab) for metastatic or unresectable locally advanced urothelial carcinoma (UC)—IKF-s614.

Authors

Igor Tsaur

Universitätsklinik Tübingen, Klinik für Urologie, Tuebingen, Germany

Igor Tsaur , Maximilian Peter Johannes Karl Brandt , Eray Goekkurt , Viktor Grünwald , Daniel Pink , Florian Roghmann , Martin Sebastian , Friedemann Zengerling , Sabine Beck , Christine Koch , Johanna Riedel , Ulas Tenekeci , Daniel Wilhelm Mueller , Salah-Eddin Al-Batran , Thorsten Goetze

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Phase I INSIGHT platform trial: Advanced safety and efficacy data from stratum D evaluating feasibility and safety of eftilagimod alpha (soluble LAG-3 protein) combined with avelumab in advanced solid tumors.

First Author: Thorsten Oliver Goetze

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

The "INSIGHT" Trial: Two new strata of an explorative, open-labeled phase I study evaluating the feasibility and safety of subcutaneous IMP321 injections (LAG-3Ig fusion protein, eftilagimod alpha) combined with either standard-of-care drug therapy or PD-L1 inhibition (avelumab) in advanced-stage solid tumor entities.

First Author: Daniel Wilhelm Mueller

insert_chart_outlined

Poster

2024 ASCO Genitourinary Cancers Symposium

bookmark_border

Preclinical testing of a novel PD-L1 inhibitor for the treatment of renal cell carcinoma.

First Author: Michelle Hsu

insert_chart_outlined

Poster

2020 Genitourinary Cancers Symposium

bookmark_border

Avelumab as single agent for patients with metastatic or locally advanced urothelial cancer PD-L1+ unfit for cisplatin: The ARIES study.

First Author: Roberto Iacovelli